Capital Flow Monitor · Sponsors · CIK 2077159
Pahr Therapeutics, Inc.
200 BERKELEY STREET, 18TH FLOOR, BOSTON, MA, 02116 · (781) 424-9384
Biotechnology · Corporation· inc. DELAWARE true 2025
Fit score
—
Offering
$14.0M
Sold
$4.7M
% sold
33.3%
Investors
4
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2025-07-18 | D ·current | 506(b) | $14.0M | $4.7M | 33.3% | 4 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
-
Neil Buckley — Executive Officer / Director / Promoter, Boston, MA
1 other raise
- Slate Medicines, Inc. $10.0M of $130.0M · 7.7%
-
Ken Horne — Director, Boston, MA
2 other raises
- Imbria Pharmaceuticals, Inc. $66.7M of $144.2M · 46.3%
- AN Venture Partners I, LP $197.0M of $197.0M · 100.0%
- Amanda Creedon — Executive Officer, Boston, MA
-
Andrew Levin — Director, Boston, MA
4 other raises
- Climb Bio, Inc. $110.1M of $110.1M · 100.0%
- Slate Medicines, Inc. $10.0M of $130.0M · 7.7%
- Lonestar Medicines, Inc. $25.0M of $45.0M · 55.6%
- Imbria Pharmaceuticals, Inc. $66.7M of $144.2M · 46.3%
- Atsushi Usami — Director, Boston, MA
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.